Global Cardiovascular Drugs Market
Global Cardiovascular Drugs Market was valued at US$ 80.5 Bn in 2017 and is expected to reach US$ 98.8 Bn by 2026, at a CAGR of 2.6 % during the forecast period.
The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding Cardiovascular Drugs market dynamics, structure by identifying and analysing the market segments and project the global market size. Further, report also focuses on competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTER’s analysis, SWOT analysis to address questions of shareholders to prioritizing the efforts and investment in near future to emerging segment in Cardiovascular Drugs market.
The global cardiovascular disease drug market is expected to witness a high growth mainly owing to rising incidences of people suffering from cardiovascular disease. Cardiovascular disease (CVD) is a class of diseases that involve the heart or blood vessels. Cardiovascular diseases are one of the leading causes of death worldwide. Cardiovascular disease includes coronary artery diseases (CAD) such as angina and myocardial infarction (heart attack). Other Cardiovascular diseases include stroke, heart failure, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, heart arrhythmia, congenital heart disease, valvular heart disease, carditis, aortic aneurysms, peripheral artery disease, thromboembolic disease, and venous thrombosis.
Based on the Drug Class, anti-coagulants agents segment is projected to lead the market and is expected to continue its dominance during the forecast period followed by anti-hyperlipidemia segment. Outline of new anti-hyperlipidemia drug such as PCSK9 Inhibitor (Praluent) and increasing incidences of hyperlipidemia is likely to boost the expansion of the segment.
Based on the Indications, hypertension was the leading revenue generating segment in 2017 and it is likely to continue its dominance during the forecast period. Antihypertensives are a class of drugs that are used to treat hypertension. Antihypertensive therapy seeks to prevent the complications of high blood pressure, such as stroke and myocardial infarction.
Based on the Distribution Channels, Hospital Pharmacies was the leading distribution channel in 2017. Cardiovascular diseases are responsible for nearly 30% of the world’s deaths annually. Thus the volume of therapeutic as well as diagnostics products dispensed by hospital pharmacies for cardiovascular diseases is high. Some of the key factors working in favor of the global hospital pharmaceuticals market are the vast rise in prevalence of chronic diseases such as cancer, diabetes, and a number of cardiovascular conditions and the rising expenditure on healthcare across emerging economies. Online and Retail Pharmacies is projected to gain market share during the forecast period.
Geographically, North America held major shares of global cardiovascular drugs market in 2016. Asia Pacific market is projected to gain market share during the forecast period and is possible to be key revenue generator in the coming years. Initiatives by local governments to attain self-sufficiency in manufacturing pharmaceuticals and incentives for generic production in countries such as Brazil, South Africa, Saudi Arabia, etc. is likely to boost market growth in South America and Middle East & Africa.
The scope of the Global Cardiovascular Drugs Markets
Global Cardiovascular Drugs Markets, by Drug Class
• Anti hyperlipidemics
Global Cardiovascular Drugs Markets, by Indications
• Coronary Artery Disease
• Peripheral Artery Disease
Global Cardiovascular Drugs Markets, by Distribution Channels
• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies
Global Cardiovascular Drugs Market, by Region
• North America
• Asia Pacific
• Middle East & Africa
• South America
Key Players Operating In Cardiovascular Drugs Market:
• AstraZeneca plc.
• Bayer AG, Merck & Co., Inc.
• Eli Lilly & Company
• Bayer Corp.
• Bristol-Myers Squibb Co.
• Daiichi Sankyo
• Johnson & Johnson
• Gilead Sciences Inc.
• Par Pharmaceutical
• United Therapeutics
• Nippon Shinyaku Co. Ltd.
• Lupin Atlantis Holdings
• Silvergate Pharmaceuticals Inc.
• TSH Biopharm Corp.
• Vectus Biosystems Ltd.
• Phasebio Pharmaceuticals
• Ablative Solutions
• Mylan Specialty
• Takeda Pharmaceutical Co.
Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.
For More Information Visit here https://www.maximizemarketresearch.com/market-report/global-cardiovascular-drugs-market/26071/
Report Published by MAXIMIZE MARKET RESEARCH https://www.maximizemarketresearch.com
Manik Baug, Vadgaon Bk,
Pune, Maharashtra 411051, India.
+91 96071 95908
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Cardiovascular Drugs Market here
News-ID: 1572055 • Views: 464
More Releases from Global Cardiovascular Drugs Market
Global Cardiovascular Drugs Market Competitive Major Vendors – Bayer, Amgen, M …
Researchmoz added Most up-to-date research on "Global Cardiovascular Drugs Market Research Report 2019" to its huge collection of research reports. Cardiovascular Drugs and Therapy is a bimonthly peer-reviewed medical journal covering pharmacotherapy as it relates to cardiology. It was established in 1987 and is published by Springer Science+Business Media on behalf of the International Society of Cardiovascular Pharmacotherapy, of which it is the official journal. The editors-in-chief are Willem J. Remme
More Releases for Drug
Biologics Drug Discovery Market
2019-2025 Biologics Drug Discovery Market Report with Depth Analysis The biologics drug discovery involves target identification, hit-to-lead stage, lead identification and optimization. The report presents a comprehensive overview, market size, shares, and growth opportunities of Biologics Drug Discovery market by product type, application, key manufacturers and key regions. Request For Free report Sample -https://www.reportsmonitor.com/request_sample/306320 Scope of the Report: Furthermore, Biologics Drug Discovery Market report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers or
Opioid Antagonist Drug Market
The global market has been prognosticated to earn demand from popular types of products such as external use, oral and applications such as household and hospital. The Company has made available another publication in its Healthcare archive of market intelligence reports, which is titled “Global Opioid Antagonist Drug Market Research Report 2018.” While the threat of substitutes and technological risks could have an unfavorable impact on the global market, potential
Drug and cosmetics
Drug and Cosmetics Conferences regards each one of the individuals to go to the On “Drug and Cosmetics” amidst October 17-October 18, 2018 in Toronto, Canada which melds brief keynote presentations, speaker talks, Exhibition, Symposia, Workshops. Drug and Cosmetics Congress is one of the meetings and conferences which will be visited by all the prestigious cosmetologists, Scientists, fiery inspectors, postgraduates, affiliations, business meanders under a solitary rooftop. DRug and cosmetics BLESSY MATHEW Program
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: email@example.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: firstname.lastname@example.org or +91-11-47067990 Report Table of Contents 1. Indispensable Advent of Microcapsules 1.1 Trajectory of Microencapsulation 1.2 Why and wherefores for Microencapsulation 2. Characterization of Microcapsules 2.1 Composition of Microcapsules 2.2 Parameters Influencing Microcapsules 3. Engineering Technology of Microcapsules 3.1 Physical Manufacturing Technologies 3.2 Physicochemical and Chemical Technologies 4. Applicability of Microcapsules 4.1 Microcapsules in Pharmaceuticals 4.2 Microcapsules in Nutraceuticals
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning